Moxilubant hydrochloride
Based on 1 publication(s) in Google Scholar
Moxilubant (CGS 25019C) hydrochloride is an orally active BLT1 antagonist. Moxilubant hydrochloride inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant hydrochloride blocks LTB4-induced neutrophil functions. Moxilubant hydrochloride inhibits ear edema and neutrophil infiltration in mice. Moxilubant hydrochloride can be used in research related to chronic obstructive pulmonary disease.
For research use only. We do not sell to patients.
- CAS No.: 146957-32-6
- Formula: C26H38ClN3O4
- Molecular Weight:492.05
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Moxilubant hydrochloride
MoreAll Leukotriene Receptor Isoforms
More
Biological Activity
Moxilubant (oral administration; single dose) hydrochloride dose-dependently inhibits LTB4-induced neutropenia in rats, with ED50 values ranging from 2 mg/kg to 11 mg/kg within 1 to 18 hours post-administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/CBYJ mice treated Arachidonic acid[1]
-
Dosage:0.1 mg/kg; 1.0 mg/kg; 3.0 mg/kg; 10.0 mg/kg
-
Administration:p.o.; single dose
-
Result:Caused a 19% reduction in edema and a 4% change in MPO activity at 0.1 mg/kg (1.5 hours post-dose).
Caused a 41% reduction in edema and a 39% reduction in MPO activity at 1.0 mg/kg (1.5 hours post-dose).
Caused a 65% reduction in edema and a 76% reduction in MPO activity at 3.0 mg/kg (1.5 hours post-dose).
Reached an ED50 of 1.4 mg/kg for edema inhibition and 1.2 mg/kg for MPO activity inhibition (1.5 hours post-dose).
Caused a 24% reduction in edema and a 3% increase in MPO activity at 1.0 mg/kg (18 hours post-dose).
Caused a 47% reduction in edema and a 25% reduction in MPO activity at 3.0 mg/kg (18 hours post-dose).
Caused a 55% reduction in edema and a 58% reduction in MPO activity at 10.0 mg/kg (18 hours post-dose).
Reached an ED50 of 5.7 mg/kg for edema inhibition and 7.7 mg/kg for MPO activity inhibition (18 hours post-dose).
Chemical Information
-
CAS No. 146957-32-6
-
Molecular Weight 492.05
-
Formula C26H38ClN3O4
-
SMILES
[H]Cl.CC(C)N(C(C)C)C(C1=CC(OC)=C(OCCCCCOC2=CC=C(C(N)=N)C=C2)C=C1)=O
-
Synonyms
CGS 25019C hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Med Chem
Discovery of Chromone Derivatives as Selective BLT1 Inhibitors for Alleviating Acute Lung Injury and Sepsis. [Abstract]2026 Feb 26;69(4):4361-4390. PMID: 41696851
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Moxilubant hydrochloride Related Classifications
HY-106929B Related Classifications
Powered by Bioz